6720457D02Rik Activators
6720457D02Rik Activators encompass a diverse set of chemical compounds that aim to amplify the functional activity of this protein through various mechanisms that intersect with the signaling pathways it is involved in. Forskolin and Isoproterenol both act to increase intracellular levels of cAMP, which in turn activates PKA; if 6720457D02Rik is regulated by PKA-mediated phosphorylation, these compounds would enhance its activity. Similarly, 8-Bromo-cAMP, as a cAMP analog, could directly activate cAMP-dependent pathways impacting 6720457D02Rik. PMA, by activating PKC, and Bisindolylmaleimide I, by inhibiting PKC, offer a two-pronged approach to modulate the activity of 6720457D02Rik depending on its relationship with PKC-regulated pathways. EGCG could lift inhibitory phosphorylation if 6720457D02Rik is negatively regulated by certain kinases, thus upregulating its activity. The increase in intracellular calcium levels by Ionomycin and the sphingolipid signaling modulation by Sphingosine-1-phosphate present additional routes to enhance 6720457D02Rik, assuming it is involved in calcium-dependent or sphingolipid-regulated signaling processes.
The modulation of phosphatase activity by Okadaic Acid, which would lead to a prolonged phosphorylated state of proteins, could indirectly result in enhanced activity of 6720457D02Rik if it is activated by phosphorylation. The use of kinase pathway inhibitors, such as U0126 and LY294002, serves to demonstrate indirect enhancement of 6720457D02Rik by reducing competitive signaling that may otherwise suppress its functional activation. U0126, which inhibits the MAPK/ERK pathway, and LY294002, which inhibits PI3K, could upregulate 6720457D02Rik activity by alleviating negative regulation exerted by these pathways. Collectively, these activators utilize a variety of biochemical mechanisms to potentially increase the activity of 6720457D02Rik by either direct activation or by removing inhibitory signals, ensuring the protein's functional activity is maximized in the cellular context.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA is a potent activator of Protein Kinase C (PKC). Upon activation, PKC phosphorylates a wide range of cellular targets. If 6720457D02Rik activity is modulated by PKC or its downstream effectors, PMA would serve to enhance its activity. | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $78.00 $270.00 | 80 | |
Ionomycin is a calcium ionophore that increases intracellular calcium levels, which can activate calcium-dependent signaling pathways. If 6720457D02Rik is part of, or is regulated by, calcium-dependent pathways, the action of ionomycin could enhance the activity of 6720457D02Rik. | ||||||
8-Bromoadenosine 3′,5′-cyclic monophosphate | 23583-48-4 | sc-217493B sc-217493 sc-217493A sc-217493C sc-217493D | 25 mg 50 mg 100 mg 250 mg 500 mg | $108.00 $169.00 $295.00 $561.00 $835.00 | 2 | |
8-Bromo-cAMP is a cell-permeable cAMP analog that directly activates cAMP-dependent pathways. This compound can be used to bypass receptors and directly activate PKA. If 6720457D02Rik is influenced by PKA-mediated phosphorylation, this compound would enhance its activity. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
EGCG is a polyphenol found in green tea that has been shown to inhibit a range of kinases. If 6720457D02Rik is negatively regulated by a kinase that EGCG inhibits, then EGCG would enhance the activity of 6720457D02Rik by lifting the inhibitory phosphorylation. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $105.00 $242.00 | 36 | |
Bisindolylmaleimide I is a specific inhibitor of PKC. If 6720457D02Rik is regulated by a protein that is in turn regulated by PKC, inhibition of PKC may relieve negative regulation and enhance 6720457D02Rik activity. | ||||||
Okadaic Acid | 78111-17-8 | sc-3513 sc-3513A sc-3513B | 25 µg 100 µg 1 mg | $291.00 $530.00 $1800.00 | 78 | |
Okadaic acid is a potent inhibitor of protein phosphatases PP1 and PP2A. By inhibiting these phosphatases, phosphorylation states can be prolonged. If 6720457D02Rik is activated by phosphorylation, okadaic acid could enhance its activity by preventing dephosphorylation. | ||||||
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $165.00 $322.00 $570.00 $907.00 $1727.00 | 7 | |
Sphingosine-1-phosphate is a lipid signaling molecule that activates sphingosine-1-phosphate receptors and downstream signaling pathways. If 6720457D02Rik functions downstream of this pathway, its activity could be enhanced by sphingosine-1-phosphate. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is an inhibitor of MEK, a key component of the MAPK/ERK pathway. If 6720457D02Rik is negatively regulated by the MAPK/ERK pathway, U0126 may indirectly enhance the activity of 6720457D02Rik by reducing inhibitory signaling. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor. If 6720457D02Rik is part of a signaling cascade that is suppressed by PI3K activity, inhibition by LY294002 could relieve this suppression and enhance the activity of 6720457D02Rik. | ||||||